Xianju Pharmaceutical (002332.SZ): The drug registration application for betastine mesylate tablets was accepted

Zhitongcaijing · 10/16 08:57

Zhitong Finance App News, Xianju Pharmaceutical (002332.SZ) issued an announcement. The company recently received a notice of acceptance of the registration of betastine mesylate tablets produced domestically from the State Drug Administration.

According to reports, betahistine mesylate tablets have a specification of 6 mg. The reference preparation is the original marketed drug. The license holder is Eisai (China) Pharmaceutical Co., Ltd., and its English name/trade name is Betahistine Mesilate Tablets/Min Jilang. Betahistine mesylate tablets were first introduced by Japan's Eisai Co. , Ltd., developed under the trade name Merislon®. Indications are for dizziness and dizziness associated with the following diseases: Meniere's disease, Meniere's syndrome, and vertigo.

The specifications of betahistine mesylate tablets declared by the company this time are consistent with the specifications listed in the reference formulation, and are declared according to the 4 types of chemicals.